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Antiretroviral treatment in the
Northern Cape
To the Editor: We would like to report on our experience with
the first 100 paediatric patients started on antiretroviral
treatment in the Northern Cape. All of these patients were on
treatment for at least 6 months.
Patients were started on treatment between August 2003 and
September 2004, with ages ranging between 3 months and 13
years (mean 66 months). They were all World Health
Organization (WHO) paediatric stages 2 and 3 (stages 1 - 3).
Eighty-six patients were from Kimberley, 13 were from other
towns in the Northern Cape and 1 was from a neighbouring
province. Two patients had received nevirapine at birth in an
attempt to prevent transmission of the virus from mother to
child.
Ninety-six patients had CD4 counts below 15%; in 28 of these
cases CD4 counts were below 5%. Only 1 patient with
bronchiectasis had a CD4 count above 20%. Eighty-two of our
patients had viral loads above 100 000 copies/ml.
Stavudine and lamivudine formed the backbone of treatment
in 98 of the patients. The choice of the third drug depended on
patient weight, previous exposure to nevirapine, treatment for
tuberculosis and viral load. Patients with viral loads greater
than 750 000 copies/ml were put on lopinavir/ritonavir.
Forty-eight patients were started on efavirenz, 38 on
lopinavir/ritonavir and 14 on nevirapine. Extra ritonavir was
added in the case of 1 patient on lopinavir/ritonavir because
the patient was also on treatment for tuberculosis.
Outcome after at least 6 months on treatment is shown in
Table I. One patient was resistant to treatment and was
changed to abacavir, ddI, lamivudine and lopinavir/ritonavir.
This patient had previously been exposed to monotherapy and
dual therapy in the private sector.  He is currently improving
on this regimen. We are working on adherence in the other 11
patients with viral loads above 100 000 copies/ml and a final
decision on resistance still has to be taken. All 72 patients with
loads below 10 000 copies/ml are doing well.
Three patients on nevirapine were changed to efavirenz. One
patient on lopinavir/ritonavir was changed to efavirenz, and 1
patient on nevirapine to lopinavir/ritonavir. No changes were
made to the nucleoside reverse transcriptase inhibitors.  
One of the 9 deaths was probably caused by AZT bone
marrow suppression. This patient was placed on AZT because
of a severe HIV encephalopathy. Three of the deaths occurred
in the first month after treatment was commenced, and 2
deaths 6 months after triple therapy was started. These 2
patients both suffered from cardiomyopathy.
It took us only 6 months to add another 100 patients to our
treatment register, and by May 2005 we had started 232
children in the Northern Cape on highly active antiretroviral
therapy.
J P Jooste






Better ultrasound service, less
misguided litigation
To the Editor: The 2005 Doctors’ Billing Manual recommends
that in pregnancy two ultrasound examinations should be paid
for by medical schemes. The first (of two) should be done
‘preferably at 10 to 14 weeks gestational age, to include Nuchal
Translucency Assessment (NTT)’ (tariff code 3615) and the
second at ’20 to 24 weeks, to include detailed anatomical
assessment’ (tariff code 3617). Only if ‘an abnormality is
suspected, such as ectopic pregnancy, abortion or a discrepancy
in dates vs. size’ can tariff code 5106 be used. It should not be
used to see if the pregnancy is normal.
But how can the doctor reasonably be expected to reassure
the patient that all is well at the first visit, which usually
happens at 6 - 9 weeks, without making use of ultrasound?
Obviously some doctors may pretend to ‘suspect’ something is
wrong and may use/abuse this tariff code (i.e. this particular
tariff code is therefore open to abuse, or let’s call it petty
fraud). It is also true that the patient’s first visit at 6 - 9 weeks
is her most exciting, her most important and intimate visit
from a personal point of view. That is the visit where she wants
to know if the fetus is in the right position, whether it is a
singleton or multiple pregnancy, and if ‘everything looks
normal’. This is especially true with the infertility patient. To
deny her an ultrasound scan at this stage seems unreasonable,
and also puts the doctor at increased risk of litigation (‘Could
you not have diagnosed the molar pregnancy earlier, doc?’, for
example). I therefore suggest that a routine early ’reassurance’
scan at the present tariff (5106) be negotiated with the medical
aids, in addition to the two scans already allowed. 
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Table I. Outcome after at least 6 months on treatment
Outcome Number
< 400 copies/ml 67
400 - 999 copies/ml 2
1 000 - 9 999 copies/ml 3
10 000 - 99 999 copies/ml 9
100 000 - 999 999 copies/ml 3
Lost to follow-up 3
Treatment stopped 3
Patient transferred 1
Patient died 9
